



Great Basin Will Exhibit at the Upcoming South Central Association for Clinical Microbiology Spring Meeting

Media Alert – Salt Lake City, April 6, 2016 – Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, will exhibit at the South Central Association for Clinical Microbiology (SCACM) Spring Meeting April 13-16 in Sandusky, Ohio. Company staff will be available to meet with fellow attendees, and demonstrate Great Basin’s easy-to-use, low cost, versatile system for performing low-plex, multiplex and direct from specimen molecular diagnostic testing.

Great Basin currently has two commercially available low-plex tests for *Clostridium difficile* (*C. diff*) and Group B *Streptococcus* (GBS). The company’s stand-alone molecular test for [Shiga toxin-producing *E. coli* \(STEC\)](#) detection, and its [Staph ID/R Blood Culture Panel](#) were recently granted U.S. Food & Drug Administration (FDA) 510(k) clearance. Great Basin’s Benchtop Analyzer is the first and only FDA cleared molecular diagnostic platform capable of running low-plex tests, multiplex panels and direct-from-specimen tests and panels.

To schedule a meeting with Great Basin representatives at SCACM, contact sales at 855-275-5288.

Founded in the 1970’s, SCACM was formed to fill the need to produce better informed microbiologists. The group has grown to close to 1,000 members since then, primarily from but not limited to, Illinois, Indiana, Kentucky, Michigan, Ohio, and West Virginia. The goals of the non-profit association include: promoting scientific knowledge of Clinical Microbiology through communication, improving education, encouraging scientific investigation, and gaining higher recognition in the field of Clinical Microbiology.

For more information about the SCACM Spring Meeting, visit <http://www.scacm.org/>.

About Great Basin Scientific

Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company's vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company's website at www.gbscience.com.

Forward-Looking Statements

This press release includes forward-looking statements regarding the Company's continuing business efforts related to its products, including but not limited to planned tests to be brought to clinical trial in 2016z, target customer group and related statements. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.

Media Contact:

Kate Ottavio Kent

ICR

203.682.8276

Kate.Ottavio-Kent@icrinc.com

Investor Relations Contacts:

Scott Gordon

CorProminence

516.222.2560

gbinfo@corprominence.com

David Clair

ICR

646.277.1266

David.Clair@icrinc.com

###